Privacy, AI and new phase of pharmaceutical research in Europe, US and China

ASIASTUDIO: Dr. Kelly H. Zou, a leading expert in statistics and former vice president at Pfizer, discusses the future of health data, drug research, and artificial intelligence with Mikko Alkio. Topics include the advances of the European Health Data Space, the unique quality of Nordic registries, the role of genomic data in preventive care, and the balance between privacy and public health. Zou also opens up about her work as an Anthropic community ambassador and compares startup ecosystems in the United States, Europe, and China. A candid and at times provocative conversation about how data could be better used for the benefit of patients.Aloita ilmainen 14 päivän kokeilu: www.asiastudio.fi. Asiastudio app on nyt ladattavissa App Storesta tai Google Playsta.00:00 Intro00:57 Zou's background04:24 Zou's books and the evolution of her research from imaging to AI09:00 Pharmaceutical industry regulation, clinical trial challenges, and data siloing10:19 The European Health Data Space and its regulatory framework13:47 Comparison of US and Nordic data sources and registry quality18:00 Differences in resources between large pharma and biotech firms, and precision data strategy19:36 Genomic data in layman's terms: biobanks, 23andMe, and the Swedish twin study23:15 Imaging, AI, and the role of genomic data in understanding the individual24:51 Genomic data privacy, GDPR, and Alkio's personal view26:53 Question about data-driven prevention at Mayo Clinic and other clinics28:00 Zou's personal experience of an early cancer diagnosis and biobank study30:47 The impact of genomic data on preventive care and research needs32:25 Alkio's example of a Spanish health center and pragmatic prevention35:40 Turning research findings into action and the role of decision-makers37:38 The role of regulators, payers, and real-world data in approval, and ARPA-H39:16 Privacy, the principle of proportionality, and Alkio's provocative question about data use42:01 Privacy in the age of generative AI and the technical challenges of data protection44:38 The contradiction between social media data and health data in privacy46:05 Data ownership and patients' rights to their own data48:54 Healthcare system incentives and Alkio's critique of the Finnish model51:23 Anthropic community ambassador work and Zou's roles52:18 AI workshop in New York, hackathon, and open data55:26 Poulevard Tech's market entry and the role of the startup community56:52 Differences in startup ecosystems on the East and West Coasts58:14 Comparison of different research and startup regions in the United States59:03 Tech Week events and customer-centricity in entrepreneurship1:01:37 Differences in entrepreneurial spirit between Europe and the United States1:02:00 Shanghai, New York, and the dynamism of cities1:03:43 Highlighting Helsinki and cultural similarities1:04:56 China's technological development in healthcare and examples1:06:38 Technology, trust, and Europe's caution, plus biometrics1:08:07 China's execution capability, democracy, and effective use of technology1:10:03 China's innovation culture and historical pride in inventions1:11:30 The responsibility of health policy, the principle of proportionality, and closing remarks1:13:44 Light closing, basketball game, and goodbyes